GlassScriptPhysician profile
Lacey Eichhorst
NPI 1154085132
$1,053.01
in general payments reported to CMS, 2019-2025
17 companies · $332 in 2025
The $332 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $373 · 2023: $290 · 2024: $57.84 · 2025: $332.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $680.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $679.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $213.85 | 2022-2025 | |
| Novo Nordisk INC | $175.80 | 2022-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $158.68 | 2022-2023 | Jardiance |
| Abbvie INC. | $109.08 | 2022-2025 | |
| Astellas Pharma US INC | $85.53 | 2025 | Veozah |
| Merck Sharp & Dohme LLC | $78.77 | 2023-2024 | Vaxneuvance, Gardasil 9, M-M-R II |
| Bayer Healthcare Pharmaceuticals INC. | $34.16 | 2022-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $31.86 | 2022 | |
| Amgen INC. | $24.72 | 2024 | Repatha |
| Abbott Laboratories | $23.12 | 2025 | Freestyle Libre 3 |
| Vanda Pharmaceuticals INC. | $22.46 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $17.85 | 2023 | |
| Corcept Therapeutics | $16.46 | 2023 | Korlym |
| Aimmune Therapeutics, INC. | $16.37 | 2025 | Vowst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.50 | 2023 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $15.06 | 2023 | Krystexxa |
| Xeris Pharmaceuticals, INC. | $13.74 | 2023 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lacey Eichhorst listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.